The need for accurate epidemiology data to drive a higher success rate with Health Technology Assessments

Most drug or device launches today require a health economic valuation often in the form of a Health Technology Assessment (HTA) to satisfy payers that the new ‘technology’ is advantageous for the health system. Most HTAs include epidemiology data in some form. This is often included in order to understand the impact of the technology…

Defining patient populations is a key trend shaping the pharma industry

Christopher Ehinger of Black Swan Analysis explores one of the key trends in the pharma industry at the moment: defining patient populations. He believes that in order to be successful in the future, the industry needs to have a better understanding of the patient populations for each individual disease. (Continued from “Enablers of drug innovation…